Beovu Generic Name & Formulations
Brolucizumab-dbll 6mg/0.05mL; soln for oph intravitreal inj; preservative-free.
Vascular endothelial growth factor (VEGF) inhibitor.
Single-dose vial (w. needle), single-dose prefilled syringe—1
Neovascular (wet) age-related macular degeneration (AMD). Diabetic macular edema (DME).
Beovu Dosage and Administration
Give by intravitreal inj. AMD: 6mg (0.05mL) once monthly (approx. 25–31 days) for the 1st 3 doses, followed by 6mg (0.05mL) once every 8–12 weeks. DME: 6mg (0.05mL) every 6 weeks (approx. 39–45 days) for the 1st 5 doses, followed by 6mg (0.05mL) once every 8–12 weeks.
Ocular or periocular infections. Active intraocular inflammation.
Beovu Boxed Warnings
Must only be administered by a qualified physician. Monitor for endophthalmitis, retinal detachments, retinal vasculitis and/or retinal vascular occlusion, elevation in IOP, and perfusion of optic nerve head following inj. Potential risk of arterial thromboembolic events (eg, nonfatal stroke or MI, vascular death). Advise females of reproductive potential to use effective contraception during and for ≥1 month after the last dose. Pregnancy. Nursing mothers: not recommended (during and for ≥1 month after the last dose).
Beovu Adverse Reactions
Vision blurred, cataract, conjunctival hemorrhage, eye pain, vitreous floaters; hypersensitivity reactions.
Beovu Clinical Trials
Beovu Patient Counseling